High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors

This publication has 26 references indexed in Scilit:

• Signaling Molecules in Overcirculation-Induced Pulmonary Hypertension in Piglets
  Circulation, 2004
• Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation
  Molecular Pharmacology, 2004
• The cGMP-binding, cGMP-specific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion
  Cellular Signalling, 2004
• Properties and Functions of GAF Domains in Cyclic Nucleotide Phosphodiesterases and Other Proteins
  Molecular Pharmacology, 2004
• Single step isolation of sildenafil from commercially available Viagra™ tablets
  International Journal Of Impotence Research, 2003
• Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension
  Circulation, 2003
• [3H]Sildenafil Binding to Phosphodiesterase-5 Is Specific, Kinetically Heterogeneous, and Stimulated by cGMP
  Molecular Pharmacology, 2003
• Sildenafil citrate does not affect cardiac contractility in human or dog heart
  Current Medical Research and Opinion, 2003
• Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension
  Circulation, 2002
• Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure
  The FASEB Journal, 2001